nivolumab,ipilimumab,cabozantinib
bms,exelixis
['nivo', 'triplet,(-triplete)', 'rcc,(-irccs),(-srcc),(-urcc)', 'ipi+', 'cosmic-313']
cosmic-313 met its primary endpoint of improved pfs (hr 0.73) for cabo+ipi+nivo vs ipi+nivo. os data is maturing and will be critical. first randomized triplet phase 3 data in rcc!! #esmo2022 
Genitourinary oncologist @DanaFarber. Opinions are my own.